Roche takes majority stake in cancer profiling firm Foundation Medicine; later buys the rest
Roche acquired the majority stake--52.4% (56.3% on a fully diluted basis)--of publicly traded Foundation Medicine Inc. (FMI; tumor genomic analysis) for $1.03bn, or 20.6mm shares for $50 (a 118% premium). The primary investment consists of 5mm shares, followed by a tender offer for 15.6mm shares. Three Roche representatives will join FMI’s board on deal closing, while FMI will continue to operate independently and retain its management team.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.